Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries has received US Food and Drug Administration (USFDA) approval for ILUMYA (tildrakizumab-asmn) used for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

The USFDA approval of ILUMYA for the treatment of adults with moderate-to-severe plaque psoriasis was supported by data from the pivotal Phase-3 reSURFACE clinical development program.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.